PRESS RELEASES

GreenLight Biosciences & EpiVax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines

January 9, 2023

GreenLight Biosciences Holdings, PBC (Nasdaq:GRNA), and EpiVax Therapeutics Inc, today announced that they have signed an exclusive collaboration agreement to jointly develop and commercialize personalized mRNA-based vaccine candidates for cancers.

Learn More

NEWS

Providence and Boston biotechs to collaborate on mRNA cancer vaccine

January 10, 2023

EpiVax, Greenlight partner to produce mRNA cancer treatments

January 9, 2023

CSE Presents Tech Tuesday - Precision Medicine in Cancer Treatment

October 18, 2022

What if the First Coronavirus Vaccines Aren't the Best?

August 27, 2020

EpiVax Oncology Prepares a Clinical Trial for Precision Medicine/Immunotherapy Cancer Treatment

January 15, 2020

How Your Genes Could be Used to Cure Cancer

August 9, 2018